Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVCAGsCD59 (JNJ-1887) for Treatment-Naive Wet AMD
NCT03585556Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JNJ-81201887 in exudative macular degeneration, sponsored by Janssen Pharmaceutical. Primary endpoint: Number of intravitreal anti-VEGF injections at 12 months. Started Sep 2018; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03585556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585556.